176894-58-9

Usage

Uses

Used in Organic Synthesis:
(R)-Benzyl 1-cyanoethylcarbaMate is used as a reagent in organic synthesis for its ability to introduce stereochemical control in chemical reactions. This property is crucial for the development of enantiomerically pure compounds, which are essential in various applications, including pharmaceuticals and agrochemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (R)-benzyl 1-cyanoethylcarbaMate serves as a valuable chiral auxiliary, aiding in the development of new drugs with improved efficacy and selectivity. Its role in asymmetric synthesis allows for the creation of chiral molecules with specific configurations, which can significantly impact the drug's activity and safety profile.
Used in Agricultural Products:
(R)-Benzyl 1-cyanoethylcarbaMate also has potential applications in the development of agricultural products, where stereochemistry plays a vital role in the effectiveness and selectivity of active ingredients. Its use in asymmetric synthesis can contribute to the creation of more targeted and environmentally friendly agrochemicals.
Overall, (R)-benzyl 1-cyanoethylcarbaMate's unique structural and chiral properties make it a valuable compound in both the chemical and pharmaceutical industries, with applications ranging from organic synthesis to the development of new drugs and agricultural products.

Upstream product

• 151378-81-3 benzyl [(1R)-2-amino-1-methyl-2-oxoethyl]carbamate 
• 26607-51-2 N-benzyloxycarbonyl-D-alanine 
• 102988-93-2 C₁₆H₂₁NO₆ 
• 28819-05-8 N-benzyloxycarbonyl-D-alanine methyl ester 

Downstream Products

• 1150262-33-1 benzyl [(1R)-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]carbamate 
• 1150566-62-3 benzyl [(1R,2Z)-2-amino-2-(hydroxyimino)-1-methylethyl]carbamate 
• 34276-31-8 benzyl N-[(1R)-1-(1H-1,2,3,4-tetrazol-5-yl)ethyl]carbamate 

Relevant academic research and scientific papers

C-terminal 1-aminoethyltetrazole-containing oligopeptides as novel alanine racemase inhibitors

In clinical culture media inoculated with patient samples, selective inhibition of commensal bacteria is essential for accurate diagnosis and effective treatment, as they can mask the presence of pathogenic bacteria. The alanine analogue, 1-aminoethyltetr

P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor s

P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

Design and synthesis of cyclopenta[g]quinazoline-based antifolates as inhibitors of thymidylate synthase and potential antitumor agents

Following the development of raltitrexed, the synthesis of nonpolyglutamatable inhibitors of TS that do not use the reduced folate carrier (RFC) for cellular entry should provide compounds which overcome mechanisms of resistance to folate-based inhibitors

Carboxylic acid bioisosteres of γ-linked dipeptide analogues of the folate-based thymidylate synthase (TS) inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)

Tetrazole carboxylic acid bioisosteres of γ-linked dipeptide derivatives of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583), a folate-based inhibitor of thymidylate synthase (TS), were synthesised by multistep routes starti